Takeda Lays Out Teva JV Impact, Confirms Blopress Transfer
This article was originally published in PharmAsia News
Executive Summary
Takeda has identified its first mature products to be transferred next April to a new joint venture with Teva, in a transaction it expects to be cash flow accretive next fiscal year despite an initial hit on revenues and operating profit.